- Aquest esdeveniment ja ha passat.
IBEC Seminar: Dan Vigneron
Dimarts, juliol 18, 2023 @ 10:00 am–11:30 am
Translation and Initial Patient and Volunteer Studies with Hyperpolarized Carbon-13 MR Molecular Imaging
Dan Vigneron, Department of Radiology & Biomedical Imaging, University of California San Francisco
“Hyperpolarized (HP) carbon-13 MRI is an emerging molecular imaging method to monitor enzymatic conversions through key, previously-inaccessible biochemical pathways. Over 1000 human HP carbon-13 MR studies to date have shown outstanding research and potential clinical value. Just as MRI has shown value for medical imaging providing information beyond CT/X-ray, HP C-13 MRI can provide new isotope imaging biomarker information in addition to what PET & SPECT do. HP C13 MRI is safe, ~2min, non-radioactive addition to standard-of-care MRI exams, at costs less than separate PET exam. At the UCSF Hyperpolarized MRI Technology Resource Center, we are developing new techniques for rapid dynamic acquisitions to measure HP conversion rates for [1-13C]pyruvate to [1-13C]lactate, [1-13C]alanine and 13C-bicarbonate in the abdomen, pelvis, heart and brain to monitor cellular metabolism in normal tissues and pathologies. We are conducting over 15 clinical trials of HP C-13 MRI and have translated 4 different HP probes into first human studies: [1-13C]pyruvate, [2-13C]pyruvate, [1-13C]alpha-ketoglutarate, and 13C-urea. Initial results demonstrate the ability to detect cancer aggressiveness, response to therapy, cardiac disease and brain bioenergetics.
Dr. Daniel B. Vigneron Ph.D. is a Professor in the Department of Radiology & Biomedical Imaging and at the University of California, San Francisco. He also has joint appointments in the Departments of Bioengineering & Therapeutic Sciences and Neurological Surgery at UCSF and is a member of the UCB/UCSF Bioengineering graduate group. He directs the UCSF Human Imaging Core and the Advanced Imaging Technologies Resource Group that facilitates imaging technique development in the Department of Radiology & Biomedical Imaging including: Hyperpolarized Carbon-13, PET-MR, and 7T MR. He also is the Director of the NIH NIBIB-funded Hyperpolarized C-13 MRI Technology Resource Center at UCSF that was recently renewed till 2027 with 20 external collaborative and service projects. This UCSF Hyperpolarized MRI Technology Resource Center also sponsors numerous training and education opportunities including symposia/workshops focused on the development and dissemination of new HP-MRI techniques. Dr. Vigneron was elected Fellow of the International Society of Magnetic Resonance in Medicine in 2009 and to the College of Fellows of the American Institute for Medical and Biological Engineering in 2007. He received the Academy of Radiology Research Distinguished Investigator Award in 2013 and with colleagues was awarded the Gold Medal of the World Molecular Imaging Society in 2014.
Dr. Vigneron obtained his BA in Chemistry from Wesleyan University in Middletown, Connecticut in 1983, and he completed his PhD research in Pharmaceutical Chemistry from UCSF in 1988 and then conducted post-doctoral research at the Fox Chase Cancer Center in Philadelphia and at UCSF developing new MRI techniques for characterizing disease and therapy response. Prof. Vigneron’s research is focused on the development of metabolic MRI techniques for research and clinical assessments of human diseases. This research has been reported in over 350 total publications resulting in over 39,000 citations with an h-index of 109 and an i10-index of 339 and has been funded by 25 NIH grant awards including as PI: 3 P41, 1 P01 2 U01, 18 R01 and 1 S10 grant awards. Also, he has served as the Primary Mentor on 6 NIH career mentored awards. Dr. Vigneron leads the technical development aspects of the hyperpolarized carbon-13 MR program at UCSF and is the Principal Investigator of seven current NIH funded projects focused on new HP metabolic MRI techniques applied to clinical research studies of prostate cancer, metastatic cancers, brain disorders and CNS tumors.
